Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or more.~* A documented diagnosis of bipolar I disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria (i.e., 296.0, 296.4 or 296.6).~* Currently displaying an acute manic (including mixed) episode according to the DSM-IV criteria.~* A Young Mania Rating Scale (YMRS) total score of 20 or greater.~* Symptoms of the current manic episode starting within 2 weeks prior to Randomization (V2, Day 1).~* Able to undergo a standard evaluation, including clinical interview, ratings and laboratory studies.~* Signed informed consent form (ICF).~* Post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or tubal ligation. In case of woman of childbearing potential, patient presents a serum pregnancy test consistent with a non-gravid state and will use double-barrier contraception until at least the post-study visit (PSV).~Exclusion Criteria:~* History of schizophrenia or schizoaffective disorder, psychotic features or rapid cycling.~* Currently treated with carbamazepine or oxcarbazepine.~* History of unresponsiveness, intolerance or hypersensitivity to related compounds (carbamazepine, oxcarbazepine or licarbazepine).~* Use of any depot-neuroleptics for the current manic episode~* Abuse of stimulating drugs or use of any systemic sympathicomimetic drug within the previous 2 weeks.~* Electroconvulsive therapy (ECT) within the previous 3 months~* History of dependence or chronic abuse from alcohol, drugs or medications within the last year.~* Judged clinically to be at risk of harm to self or others.~* Second or third-degree atrioventricular blockade not corrected with a pacemaker.~* Relevant ECG or laboratory abnormalities.~* Calculated creatinine clearance \<30 ml/min \[men: (140-age) x weight / serum creatinine x 72; women: (0.85) (140-age) x weight / serum creatinine x 72. Age in years, weight in kg, and serum creatinine in mg/dl\].~* Pregnancy or nursing.~* Participation in other drug clinical trial within the last 2 months before Randomization visit~* Not ensured capability to perform the trial or to comply with the study protocol (e.g. mental retardation or severe inability to communicate);~* Any other uncontrolled clinically relevant disorder.~* Previous treatment with Eslicarbazepine Acetate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Eslicarbazepine acetate 1800 mg
- Group 2 (Type: EXPERIMENTAL): Eslicarbazepine acetate 1200 mg
- Group 3 (Type: EXPERIMENTAL): Eslicarbazepine acetate 600 mg
- Group 4 (Type: PLACEBO_COMPARATOR): Placebo pills

Based on this trial design, predict the completion outcome and termination type (if applicable).